Phase III trial of CAM 2029 in patients with acromegaly and neuroendocrine tumors

Trial Profile

Phase III trial of CAM 2029 in patients with acromegaly and neuroendocrine tumors

Planning
Phase of Trial: Phase III

Latest Information Update: 03 May 2018

At a glance

  • Drugs Octreotide (Primary)
  • Indications Acromegaly; Neuroendocrine tumours
  • Focus Therapeutic Use
  • Sponsors Camurus
  • Most Recent Events

    • 03 May 2018 According to a Camurus AB media release, the company has regained worldwide development and commercialization rights from Novartis to CAM2029 (Octreotide) and it plans to initiate phase III program during the first half of 2019.
    • 26 Oct 2017 According to a Camurus media release, the start of Phase 3 trials has been postponed in order to evaluate new study designs recently suggested by health authorities, and to conduct additional manufacturing and packaging activities. Discussions with US FDA anticipated for early 2018 may result in an earlier study completion compared with current designs.
    • 19 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top